TY  - GEN
AU  - Janmaat,Maarten L
AU  - Gallegos-Ruiz,Mariëlle I
AU  - Rodriguez,José A
AU  - Meijer,Gerrit A
AU  - Vervenne,Walter L
AU  - Richel,Dick J
AU  - Van Groeningen,Cees
AU  - Giaccone,Giuseppe
TI  - Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
SN  - 1527-7755
PY  - 2006///0413
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Esophageal Neoplasms
KW  - drug therapy
KW  - Extracellular Signal-Regulated MAP Kinases
KW  - metabolism
KW  - Female
KW  - Gefitinib
KW  - Gene Dosage
KW  - Genes, ras
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Phosphatidylinositol 3-Kinases
KW  - genetics
KW  - Phosphorylation
KW  - Proto-Oncogene Proteins c-akt
KW  - Quinazolines
KW  - adverse effects
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2005.03.4900
ER  -